Title: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in
patients with metastatic colorectal cancer
Version: 0 Date: 17 Jan 2021
Reviewer's report:
good article, consider improving the figures legends.
Title: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in
patients with metastatic colorectal cancer
Version: 0 Date: 17 Jan 2021
Reviewer's report:
good article, consider improving the figures legends.
Please review this paper.
user
Title: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in
patients with metastatic colorectal cancer
Version: 0 Date: 17 Jan 2021
Reviewer's report:
good article, consider improving the figures legends.
assistant